STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|---|
May 08, 2025 |
Jun. 25, 2025 |
Jul. 31, 2025 |
Jul. 31, 2024 |
Jul. 31, 2025 |
Jul. 31, 2024 |
|
| Stock compensation costs | $ 3,937,000 | $ 2,751,000 | ||||
| Purchased of warrants | 55,000 | |||||
| Exercisable for a period | 5 years | |||||
| Exercise price | $ 2.86 | |||||
| BioLumina, LLC [Member] | ||||||
| Warrants description | Company received notice from a holder of warrants to exercise 21,277 warrants to purchase 21,277 shares of common stock of the Company for a total exercise price of $50,000 ($2.35 per share). The proceeds were received, and the shares were issued on July 30, 2025. | |||||
| Equity Option [Member] | ||||||
| Stock compensation costs | $ 722,000 | $ 173,000 | 1,236,000 | 692,000 | ||
| Unamortized compensation costs | 670,000 | 670,000 | ||||
| Warrant [Member] | ||||||
| Stock compensation costs | 958,000 | $ 586,000 | 2,578,000 | $ 1,640,000 | ||
| Unamortized compensation costs | 1,678,000 | $ 1,678,000 | ||||
| Director [Member] | ||||||
| Options granted | 11,341 | |||||
| Vesting period | options vest annually over 3 years, expire five years from the date of grant | |||||
| Option grant date fair value | 39,000 | $ 39,000 | ||||
| Options forfeited | 7,147 | |||||
| Dr. Everts [Member] | ||||||
| Options granted | 65,000 | |||||
| Vesting period | options vest over a five-year periods | |||||
| Option grant date fair value | $ 177,125 | $ 177,125 | ||||
| Employees, officers and directors [Member] | ||||||
| Grant of unvested restricted common stock | 165,000 | |||||
| Fair value of the shares as of the date of grant | $ 472,000 | |||||
| Consultant [Member] | Consulting Agreement [Member] | ||||||
| Grant of unvested restricted common stock description | In connection with the Consulting Agreement discussed in Note 11, the Company granted the Consultant warrants to purchase 500,000 shares of its common stock (the “Warrants”). The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable based upon meeting certain conditions provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%. | |||||